Century Therapeutics, Inc. (NASDAQ:IPSC) – Investment analysts at SVB Leerink boosted their Q1 2022 earnings per share (EPS) estimates for shares of Century Therapeutics in a research note issued on Monday, January 10th. SVB Leerink analyst D. Graybosch now anticipates that the company will post earnings of ($0.06) per share for the quarter, up from their previous estimate of ($0.42). SVB Leerink currently has a “Outperform” rating and a $32.00 target price on the stock. SVB Leerink also issued estimates for Century Therapeutics’ Q2 2022 earnings at ($0.31) EPS, Q3 2022 earnings at ($0.31) EPS, Q4 2022 earnings at ($0.32) EPS, FY2022 earnings at ($1.00) EPS, Q1 2023 earnings at ($0.33) EPS, Q2 2023 earnings at ($0.34) EPS, Q3 2023 earnings at ($0.35) EPS, Q4 2023 earnings at ($0.36) EPS, FY2023 earnings at ($1.37) EPS, FY2024 earnings at ($1.53) EPS and FY2025 earnings at ($1.58) EPS.
Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, November 10th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.08).
Shares of IPSC opened at $14.49 on Thursday. Century Therapeutics has a twelve month low of $12.47 and a twelve month high of $32.90. The firm’s fifty day simple moving average is $16.84 and its 200-day simple moving average is $22.63. The company has a debt-to-equity ratio of 0.03, a quick ratio of 15.12 and a current ratio of 15.12.
A number of large investors have recently made changes to their positions in IPSC. Monashee Investment Management LLC acquired a new stake in Century Therapeutics during the 2nd quarter worth $1,760,000. Legal & General Group Plc acquired a new stake in Century Therapeutics during the 2nd quarter worth $29,000. FMR LLC acquired a new stake in Century Therapeutics during the 2nd quarter worth $141,004,000. Vanguard Group Inc. acquired a new stake in Century Therapeutics during the 2nd quarter worth $880,000. Finally, Geode Capital Management LLC acquired a new stake in Century Therapeutics during the 2nd quarter worth $1,134,000. Hedge funds and other institutional investors own 36.24% of the company’s stock.
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
See Also: What is an economic bubble?
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.